Home
NewsNewsCSG.BIO has gone ahead with the acquisition of Hanabusa IVF, Asian Egg Bank, thereby making it a world leader in reproductive medicine and cutting-edge clinics with enhanced patient reach and advanced laboratory capabilities.
On March 5, 2026, CSG.BIO, which is a global life sciences and healthcare platform with services across fertility, reproductive health, and biologic preservation, as well as family-building, went ahead with the acquisition of Hanabusa IVF, Asian Egg Bank.
Hanabusa IVF, which is based in San Diego, California, is known for its customised fertility care, which includes its unique approach when it comes to mini-IVF along with lower-stimulation treatments. Asian Egg Bank is now one of the leading options for intended parents and fertility clinics to find Asian donor eggs. The two groups together give CSG.BIO a strong platform for reproductive care and donor eggs that is becoming more important in the US and around the world.
The acquisition of Hanabusa IVF, Asian Egg Bank, adds to the present speciality IVF practice of CSG.BIO, the New England Fertility Institute in Stamford, Connecticut. It turns CSG.BIO into a world leader when it comes to reproductive medicine, with cutting-edge clinics located near major domestic as well as international gateways on both coasts. This next phase helps Hanabusa IVF and New England Fertility Institute work together toward a bigger long-term goal – making personalised fertility care more available, establishing internationally connected surrogacy along with third-party reproduction services, and continuing to expand their specialised mini-IVF offering within the large global network of CSG.BIO.
It is well to be noted that the strategic fit is just as crucial to the Asian Egg Bank. Other organisations in the group include CryoChoice and AlphaCord, as well as CellSave. This kind of sync creates real synergy between family-building support and biologic storage along with reproductive services, and it also makes the infrastructure much stronger when it comes to future growth.
“Joining CSG.BIO gives us the opportunity to build on what makes Hanabusa IVF and Asian Egg Bank so distinctive while gaining the strength of a broader global platform,” said Peter Fuzesi, CEO of Hanabusa IVF and Asian Egg Bank. “We see strong alignment between our mission and CSG.BIO’s capabilities across fertility, preservation, and family-building services. This next step allows us to continue advancing personalised care in San Diego while expanding what we can offer patients, intended parents, and partners around the world.”
“We are thrilled to welcome Hanabusa IVF and Asian Egg Bank into the CSG.BIO family,” said Sarah Al-Hajali, CEO of CSG.BIO. “Hanabusa IVF has built an exceptional reputation for thoughtful, patient-centred fertility care, and Asian Egg Bank adds an important and highly specialised donor egg platform to our growing organisation. Together, these additions strengthen our vision for the future of reproductive medicine, family building, and biologic preservation, and we are excited for what lies ahead.”
Provident Healthcare Partners gave Hanabusa IVF and Asian Egg Bank advice on the transaction by helping it go through. Corbel Capital Partners, an independent investment firm that is based in Los Angeles that executes customised structured debt or equity investments in lower-market businesses and works with management to create value, provided the financing for the deal.
IVF bills can hit $30,000, creating major financial barriers for families. The HOPE with Fertility Services Act aims to mandate insurance coverage for infertility diagnosis, treatment, and preservation, potentially benefiting 133 million Americans while addressing affordability and expanding access to essential reproductive healthcare services across the United States.
ASEAN's First Telemedicine IVF by Inspire IVF introduces a new era of remote fertility care. Combining AI technology with expert consultation, the platform enables global access, real-time monitoring, and personalised treatment planning, positioning Thailand as a leading hub for fertility services and advancing digital transformation in reproductive healthcare.
A new Alabama bill seeks to protect access to IVF and contraceptives in Huntsville and statewide. Proposed by Rep. Marilyn Lands, the legislation aims to safeguard reproductive healthcare, prevent restrictions on federally approved treatments, and support both patients and providers amid ongoing legal and policy debates surrounding fertility and contraception access.
Kindbody and Future Family partner to expand access to fertility care through flexible financing and personalised clinical support. Offering up to $50,000 in funding, concierge guidance, and inclusive services, the collaboration helps reduce financial barriers, enabling more individuals and families to pursue IVF and other reproductive treatments with confidence.
A wearable biosensor for IVF treatments developed by Symex Labs in partnership with the University of Melbourne and Monash IVF enables real-time hormone monitoring through a skin patch. By reducing reliance on invasive blood tests, the innovation improves patient comfort, enhances treatment precision, and expands access to fertility care, particularly for patients in remote and underserved regions.
Alma Matter and Twig Fertility Partners to elevate the postpartum journey of patients by offering patients hands-on and in-home postpartum support ensuring comfort and comprehensive well-being.
